ALX Oncology Shares Rise on Positive Response and Survival Data in Phase 1b Gastric Cancer Trial
Source: Streetwise Reports  (7/6/21)
Shares of ALX Oncology Holdings Inc. traded 10% higher after the company reported new data from its Phase 1b ASPEN-01 study of ALX148 demonstrated a robust objective response in patients with gastric or gastroesophageal junction cancer. More >

Alector Partners with GSK to Develop Monoclonal Antibodies for Neurodegenerative Diseases
Source: Streetwise Reports  (7/2/21)
Alector Inc. shares traded 59% higher after the company announced it entered into a global collaboration agreement with GlaxoSmithKline to develop and advance two first-in-class, clinical stage monoclonal antibodies for treating neurodegenerative diseases including frontotemporal dementia, amyotrophic lateral sclerosis, Parkinson's and Alzheimer's. More >

Pulse Bio Shares Beat Higher on Launch of CellFX NPS System in Canada
Source: Streetwise Reports  (7/1/21)
Pulse Biosciences shares traded 27% higher after the company announced it secured a $50 million private placement one day after it reported the first CellFX® procedure using its proprietary Nano-Pulse Stimulation technology had been performed in Canada. More >

Coverage Initiated on Developer of Psychedelic Drugs for PTSD, Smoking Cessation
Source: Streetwise Reports  (6/30/21)
The investment thesis for Mydecine Innovations Group is presented in a ROTH Capital Partners report. More >

Diverse Pipeline for Repurposing Drug Company Includes Treatments for Idiopathic Pulmonary Fibrosis and Chronic Cough, Pancreatic Cancer and Stroke
Source: Streetwise Reports  (6/30/21)
Repurposing extends a drug's reach and value, and Algernon Pharmaceuticals' strategy of finding and demonstrating new uses for existing drugs reduces risk, accelerates time to market and increases capital efficiency. More >

Biotech Takes a 'Disruptive Drug Development Approach' to Destroy Dysregulated Transcription in Cancer
Source: Streetwise Reports  (6/30/21)
Kronos Bio's key assets are reviewed in an H.C. Wainwright & Co. report. More >

Cerevel Shares More Than Double on Positive Topline Results in Phase 1b Schizophrenia Trial
Source: Streetwise Reports  (6/29/21)
Shares of Cerevel Therapeutics hit a new 52-week high after the company released positive topline results for its CVL-231 in a Phase 1b clinical trial in schizophrenia patients. More >

Intellia Shares Rise 49% on 'Landmark' Interim Results in Phase 1 ATTR Amyloidosis Trial
Source: Streetwise Reports  (6/28/21)
Intellia Therapeutics soared to a new 52-week high after the firm reported that in a Phase 1 clinical study with partner Regeneron, it had achieved "landmark clinical data" that demonstrated deep reduction in disease-causing protein after a single infusion of NTLA-2001, an investigational CRISPR therapy for transthyretin (ATTR) amyloidosis.

More >

Eli Lilly Receives FDA Breakthrough Therapy Designation for Alzheimer's Treatment
Source: Streetwise Reports  (6/24/21)
Eli Lilly and Co's shares traded 8% higher and reached a new 52-week high after the company reported the FDA granted its investigational antibody therapy donanemab Breakthrough Therapy designation for use in treating Alzheimer's disease. More >

Price Target Raised on Biopharma Achieving Positive Atopic Dermatitis Study Results
Source: Streetwise Reports  (6/23/21)
Aclaris Therapeutics' new clinical trial data and a recent financing are discussed in an H.C. Wainwright & Co. report. More >

Biotech Reports Encouraging Efficacy Data in Wet AMD, Target Price Raised 66%
Source: Streetwise Reports  (6/23/21)
These new results, from a Clearside Biomedical trial, are presented and interpreted in a ROTH Capital Partners report. More >

Analyst: Health Care Services/Tech Firm's 'Biggest Transaction Gets Even Bigger'
Source: Streetwise Reports  (6/23/21)
How the acquisition has grown and its effects on CloudMD Software & Services are addressed in a Research Capital Corp. report. More >

3D Systems and CollPlant Biotech to Create Bioprinted Breast Reconstruction Treatment Solutions
Source: Streetwise Reports  (6/22/21)
3D Systems Corp. shares rose 27% after the company reported it is partnering with CollPlant Biotechnologies to develop bioprinted solutions use to improve breast reconstruction treatments. More >

Anavex Posts Strong Correlated Biomarker Data in Phase 2 Adult Rett Syndrome Trial
Source: Streetwise Reports  (6/21/21)
Anavex Life Sciences shares traded 13% higher after the company reported that ANAVEX®2-73 (blarcamesine) biomarker correlated highly with the predetermined efficacy endpoints in its Phase 2 clinical trial of adult patients with Rett syndrome. More >

Entera Bio Granted Patent for Oral Parathyroid Hormone by EU Patent Authority
Source: Streetwise Reports  (6/17/21)
Entera Bio shares traded 25% higher after the firm received a foundational patent from the EU patent office for its oral parathyroid hormone using its platform oral protein delivery technology to treat osteoporosis and hypoparathyroidism. More >

Biotech Reports Positive Preclinical COVID-19 Study Results
Source: Streetwise Reports  (6/16/21)
These data and next steps for Novan's antiviral SB019 are provided in a ROTH Capital Partners report. More >

Immuno-oncology Firm Advances Lead Asset in Mesothelioma
Source: Streetwise Reports  (6/16/21)
The status of ONCOS-102 in several of Targovax's development programs is discussed in an H.C. Wainwright & Co. report. More >

Altimmune Posts Positive Interim Weight Loss Results in Phase 1 ALT-801 Trial
Source: Streetwise Reports  (6/16/21)
Altimmune Inc. shares traded 16% higher after the company reported positive interim data from a Phase 1 study of ALT-801 in overweight and obese trial participants. More >

Clearside Biomed Shares Rise 37% on Positive Data in Phase 1/2a Wet AMD Trial
Source: Streetwise Reports  (6/15/21)
Clearside Biomedical shares reached a new 52-week high after the company reported that the first cohort in its dose-escalating Oasis Trial of CLS-AX for treatment of neovascular age-related macular degeneration met all primary endpoints. More >

Enochian Bio's Shares Rise 54% After FDA Accepts Pre-IND Request for Potential HIV Cure
Source: Streetwise Reports  (6/14/21)
Shares of Enochian Biosciences Inc. traded higher after the company reported that the U.S. Food and Drug Administration accepted a pre-investigational new drug request for a potential functional cure or treatment for human immunodeficiency virus. More >

Sorrento's COVID Test Approved in Mexico
Source: Streetwise Reports  (6/9/21)
This and other recent developments involving Sorrento Therapeutics' pipeline and partners are covered in a Dawson James Securities report. More >

Tilray Shares Climb Higher on Roll Out of New Medical Cannabis Brand Symbios
Source: Streetwise Reports  (6/9/21)
Tilray Inc. shares traded 11% higher after the company reported the launch of a new medical cannabis brand, Symbios, designed to provide medicinal users with a broader spectrum of formats and cannabinoid potencies at improved price points. More >

Promising Psychedelic Drug Trials Show Potential for a New Biotech Boom
Source: McAlinden Research for Streetwise Reports  (6/4/21)
McAlinden Research Partners notes that continued advances in psychedelic therapies show potential to drive an investment boom that could reshape the future of medicine and mental health therapies. More >

Kindred Bio Shares Rise 29% after Achieving 100% Survival Rate in Canine Parvovirus Study
Source: Streetwise Reports  (6/3/21)
Kindred Biosciences Inc. shares reached a new 52-week high after the company reported its parvovirus monoclonal antibody, KIND-030, demonstrated highly positive results in preventing deaths in dogs infected by parvovirus. More >

Drug Repurposing Firm Launches Clinical Research Program in Pancreatic Cancer
Source: Streetwise Reports  (6/3/21)
Based on various positive preclinical and clinical studies, Algernon Pharmaceuticals is pursuing Ifenprodil as a potential treatment for pancreatic tumors. More >